CStone and Kimia Therapeutics Enter Clinical Development Collaboration to Advance a Novel Drug Candidate Targeting Repair Pathways Critical for Solid Tumor Survival
SUZHOU, China, Nov. 3, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that it has...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 116 stories mentioning NOV, the earliest published 27 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.